Compare CRWS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | SKYE |
|---|---|---|
| Founded | 1957 | 2012 |
| Country | United States | United States |
| Employees | 168 | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 24.2M |
| IPO Year | 1994 | 2013 |
| Metric | CRWS | SKYE |
|---|---|---|
| Price | $2.78 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 31.0K | ★ 199.5K |
| Earning Date | 02-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.51 | N/A |
| 52 Week Low | $2.35 | $0.57 |
| 52 Week High | $3.38 | $5.75 |
| Indicator | CRWS | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 52.64 |
| Support Level | $2.49 | $0.71 |
| Resistance Level | $2.94 | $1.14 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 44.44 | 29.19 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.